Market revenue in 2023 | USD 368.0 million |
Market revenue in 2030 | USD 1,399.3 million |
Growth rate | 21% (CAGR from 2023 to 2030) |
Largest segment | Autologous therapies |
Fastest growing segment | Allogeneic Therapies |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Allogeneic Therapies, Autologous Therapies |
Key market players worldwide | Novartis AG ADR, Gilead Sciences Inc, Bristol-Myers Squibb Co, Johnson & Johnson, JCR Pharmaceuticals Co Ltd, JW (Cayman) Therapeutics Co Ltd Ordinary Shares, Atara Biotherapeutics Inc, Medipost, Beiersdorf AG, Nkarta Inc Ordinary Shares |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to cell therapy market will help companies and investors design strategic landscapes.
Autologous therapies was the largest segment with a revenue share of 68.13% in 2023. Horizon Databook has segmented the South Korea cell therapy market based on allogeneic therapies, autologous therapies covering the revenue growth of each sub-segment from 2018 to 2030.
The South Korea cell therapy market is expected to exhibit lucrative growth due to various strategic initiatives undertaken by local players and international companies. The COVID-19 pandemic led to an increase in stem cell therapies for treating the condition. For instance, in August 2022, Panacell Biotech announced that it would be using Natural Killer (NK) cells, brown Adipose-Derived Stem Cells (ADSC), and exosomes for treating COVID-19 infection.
Furthermore, several companies are focusing on cell & gene therapy and tissue-based products. Industry participants are undertaking numerous strategies to remain competitive in the country. For instance, in April 2022, Daewoong Pharmaceutical collaborated with UCI Therapeutics for CAR-NK cell therapy development.
Under the partnership, the two organizations would cooperate in inventing immune cell therapy based on their production capabilities and cell therapy development technologies. Such collaborations among key players for the development of cell therapy are expected to boost the market over the forecast period.
Horizon Databook provides a detailed overview of country-level data and insights on the South Korea cell therapy market , including forecasts for subscribers. This country databook contains high-level insights into South Korea cell therapy market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account